GRAM POSITIVE BACTERIAL INFECTIONS MARKET ANALYSIS

Gram Positive Bacterial Infections Market, by Drug Class (Antibiotic (B Lactam, Quinolones, Macrolides, Tetracyclines, Aminoglycosides, Sulphonamides, Phenicols, and Others), Antifungal, and Others), by Indication (MRSA Infections, MSSA Infections, Sinusitis, Cellulitis, Pneumonia, Otitis, Pharyngitis, and Others), by Route of Administration (Enteral, Parenteral, and Others), by Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Nov 2024
Code : CMI2654
Formats :
Excel and PDF
Industry : Pharmaceutical

Gram Positive Bacterial Infections MarketSize and Trends

Gram Positive Bacterial Infections Market Drivers

Increasing drug approvals are expected to propel growth of the gram positive bacterial infections market. For instance, in October 2018, Paratek Pharmaceuticals, Inc. received approval from the U.S. Food and Drug Administration for NUZYRA (for injection), which contains an Omadacycline. This drug is used for treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).

Increasing drug launches are expected to drive the gram positive bacterial infections market growth. For instance, in March 2017, Pfizer launched its new drug, Zavicefta, which contains combination of Avibactam and Ceftazidime. This drug is used for the treatment of intra- abdominal infections.

GRAM POSITIVE BACTERIAL INFECTIONS MARKET ANALYSIS

Gram Positive Bacterial Infections MarketSize and Trends

Gram Positive Bacterial Infections Market Report Snapshots

EXISTING CLIENTELE